Mythic Therapeutics key facts
- Developer of a biotechnology product platform designed to deliver chemotherapy directly to tumors through antibody-drug conjugates.
- Mythic Therapeutics’s last known valuation is $293.0M (Dec 2021).
- It has raised $156.5M across 4 recorded rounds; the latest was Early Stage VC ($29.9M) in Dec 2024.
- Notable investors include Viking Global Investors, BoxGroup, First Round Capital, Raptor Group, Venrock — 17 tracked in total.
- Mythic Therapeutics has filed 3 Form Ds with the SEC since 2020, most recently Dec 2024 ($29.9M sold to 30 investors).
- Status: Out of Business.
Who backs Mythic Therapeutics
17+- ·The complete investor list: 17 names
- ·Watch Mythic Therapeutics: the Monday email on marks, rounds and moves
Mythic Therapeutics funding rounds
4 roundsMythic Therapeutics valuation
Mythic Therapeutics's last known valuation is $293 million, from Dec 2021. The figure stands until a priced round, a secondary trade or an institutional fund mark prices the stock again.
How much has Mythic Therapeutics raised?
Mythic Therapeutics has raised $156 million across 4 recorded rounds since 2018. The largest was a $4.7 million seed round in Jun 2018; the most recent was a $29.9 million early-stage round in Dec 2024.
Mythic Therapeutics has filed 3 Form Ds with the SEC since 2020, most recently in Dec 2024 ($29.9 million sold to 30 investors).
Mythic Therapeutics investors
17 investors are on record for Mythic Therapeutics, including Viking Global Investors, BoxGroup, First Round Capital and Raptor Group. By type, the record holds 6 venture capital firms, 2 hedge funds and 1 asset manager. The early-stage round in Dec 2024 drew 30 investors.
Comparable companies
Comparable drug discovery names by valuation on PrivateMarketView: City Therapeutics ($285 million), Convergent Therapeutics ($280 million) and Ensoma ($280 million).
About Mythic Therapeutics
Developer of a biotechnology product platform designed to deliver chemotherapy directly to tumors through antibody-drug conjugates. The company's technology increases uptake in cancerous cells while avoiding payload release in normal cells, increases efficacy for a wide range of targets and cancer types without causing unacceptable side effects or toxicity, enabling medical practitioners to realize the full potential of patients, treat a broad array of tumor targets and leave a lasting impact on cancer care.
- Industry
- Drug Discovery
- Sector
- Healthcare
- HQ
- Waltham, MA, United States
- Founded
- 2017
- Employees
- 14
- Website
- mythictx.com/
- Ownership
- Out of Business
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
Mythic Therapeutics’s last known valuation, Dec 2021. A PrivateMarketView mark is published once fund marks, secondary prints or a priced round let us confirm it.